Show simple item record

Transition period of child and adolescent toAdults treated with Growth HormoneRecombinant (RHGH). A reality

dc.creatorCarvajal Martínez, Francisco
dc.creatorPiz Ramos, Yuraimi
dc.creatorCarvajal Aballe, Mónica
dc.date2020-06-17
dc.date.accessioned2020-09-09T19:44:07Z
dc.date.available2020-09-09T19:44:07Z
dc.identifierhttps://revistas.intec.edu.do/index.php/cisa/article/view/1767
dc.identifier10.22206/cysa.2020.v4i2.pp13-20
dc.identifier.urihttps://repositoriobiblioteca.intec.edu.do/handle/123456789/2779
dc.descriptionThe sort stature due to growth hormone deficiency is one of the most frequent endocrine cause. The treatment is carried out with recombinant growth hormone (rhgh) for a period of usually long duration. There is a group of patients treatment with growth hormone does not end in adulthood and should also be treated at that period of life. The issue of transfers we first raises in United States in 1984, as a consequence of the significant increase in survival during 1970-1080 in children with chronic and disabling diseases. The transition period from child to adult represents a crucial phase in the growth process where multiple physical and psychosocial changes occur. It has been arbitrarily defined as the period extending from late puberty to full adult maturity. It is necessary to reassessment patient with Growth Hormone Deficiency after that to arrive the adult height and to define the GH secretion status for to evaluate the continuity of replace treatment during the transition and adult period.en-US
dc.descriptionLa baja talla por Deficiencia de Hormona de Crecimiento es una de las causas endocrinas más frecuentes. El tratamiento se realiza con hormona de crecimiento recombinante (rhgh) durante un período habitualmente de larga duración. Existe un grupo de pacientes que su tratamiento con hormona de crecimiento no concluye en la adultez y debe ser tratado también en ese periodo de la vida. El tema de las transferencias se planteó por primera vez en Estados Unidos en 1984, como consecuencia del importante aumento de supervivencia durante los años setenta y ochenta de niños con patología crónica y discapacitante. Se entiende por transición a una etapa de cambios físicos y psicológicos que, de forma arbitraria, se extiende desde el final de la pubertad hasta que la maduración adulta se completa. Es preciso reevaluar los pacientes con deficiencia de hormona de crecimiento tras alcanzar la talla adulta y definir el estado de la secreción de GH para valorar la conti el periodo de transición y en la adultez.es-ES
dc.formatapplication/pdf
dc.formattext/html
dc.languagespa
dc.publisherIntituto Tecnológico de Santo Domingo (INTEC)es-ES
dc.relationhttps://revistas.intec.edu.do/index.php/cisa/article/view/1767/2291
dc.relationhttps://revistas.intec.edu.do/index.php/cisa/article/view/1767/2316
dc.relation/*ref*/Witt JM, Rekers LT, Tuers GB, Drowe B, Beck TJ, et al. Growth hormone treatment to finally height in children with idiopathic short stature: Evidence for a dose effects. J Pediatr. 2005; 146:45-53 2. Wilson TA, Rose SR, Cohen P, et al. Update of guidelines for the use of growth hormone in children: The LawsonWilkins Pediatric Endocrinology Society Drug and Therapeutics Committee, J. Pediatr. 2003;143:415–21. 3. Blum RW. Introduction. Pediatricas. 2002; 110:1301-3. 4. Blum RW, Garell D, Hodgman CH, et al. Transition from child centred to adult health-care systems for adolescents with chronic conditions. A position paper of the Society of Adolescent Medicine. J Adolesc Health 1993; 14:570-6. 5. Argente J, Álvarez-Escolá C, de Miguel-Novoa P. Tratamiento con hormona de crecimiento en el período de transición del niño al adulto. Rev Horm Crecim. 2011;16:105-6. 6. Kapellen TM, Kiess, W. Transition of adolescents and Young adults with endocrine diseases to adult health care. Best Prac Res Clin Endocrinol Metab.2015; 29(3):505-13. 7. Clayton P, Gleeson H, Monson J, et al. Growth hormone replacement throughout life: Insights into age-related responses to treatment. Growth Horm IGF Res. 2007;17:369-82. 8. Savage MO, Drake WM, Carroll PV, et al. Transitional care of GH deficiency: When to stop GH therapy. Eur J Endocrinol. 2004; 151:S61-65. 9. Downing J, Gleeson HK, Clayton PE, et al. Transition in endocrinology: the challenge of maintaining continuity. Clin Endocrinol 2013; 78:29-35. 10. Álvarez CE, Fernández J. M, Recio et al. Documento de consenso del área de conocimiento de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición para el abordaje del hipopituitarismo durante la transición. Endocrinol Nutr. 2014;61(2):1-11. 11. Motlich ME, Clemmons DR, Malowzowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical practice guideline. J Clin Endocrinol Metab 2012; 96:1587-609. 12. Clayton PE, Shalet SM. Difficulties in patient management associated with the transition period. Guidelines of themanagement of the young GHD adult. Horm Res 2005;64(Suppl. 2):74-5. 13. Sawicki GS, Kelemen S, Weitzmann ER. Ready, set, stop: mismatch between self-care beliefs, transition readiness skills, and transition planning among adolescents, young adults and parents. Clin Pediatr. 2014; 53:1062. 14. Radovick S, DiVall S. Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab. 2007; 92:1195-2000. 15. Geffner ME. Transition to the adult endocrine clinic; testing pituitary function what test and when? Growth Horm IGF Res. 2003; 13:117-21. 16. Maghnie M, Strigazzi C, Tinelli C, et al. Growth hormone (GH) deficiency (GHD) of childhood onset: Reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab. 1999; 84:1324-8. 17. Inzaghi E, Cianfarani S. The challenges of growth hormone deficiency diagnosis and treatment during the transition from puberty to adulthood. Front Endocrinol. 2013; 4:1-8. 18. Dörr HG, Hauffa BP, Wallaschowski H, for the national KIGS and KIMS Boards. Management of adolescents with childhood onset growth hormone deficiency in the transition e results of a field based study in Germany. Dtsch Med Wochenschr 2009; 134:2551-5. 19. Leong GM, Johannsson G. Growth hormone deficiency: Strategies and indications to continue growth hormone therapy in transition from adolescence to adult life. Horm Res. 2003; 60:78-85.
dc.rightsDerechos de autor 2020 Ciencia y Saludes-ES
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0es-ES
dc.sourceScience and Health; Vol 4 No 2 (2020): Science and Health, may-August; 13-20en-US
dc.sourceCiencia y Salud; Vol. 4 Núm. 2 (2020): Ciencia y Salud, mayo-agosto; 13-20es-ES
dc.source2613-8824
dc.source2613-8816
dc.source10.22206/cysa.2020.v4i2
dc.subjectTransition perioden-US
dc.subjectGrowth Hormone Deficiencyen-US
dc.subjecthypopituitarismen-US
dc.subjectshort statureen-US
dc.subjectperíodo de transiciónes-ES
dc.subjecthipopituitarismoes-ES
dc.subjectdeficiencia de hormona de crecimientoes-ES
dc.titleTransition period of child and adolescent toAdults treated with Growth HormoneRecombinant (RHGH). A realityen-US
dc.titlePeríodo de transición del niño y el adolescente a la adultez tratado con Hormona de Crecimiento Recombinante (RHGH). Una realidades-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record